BDNF Val66Met variant and age of onset in schizophrenia

Authors

  • Helen M. Chao,

    Corresponding author
    1. Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York
    2. New York University Medical Center, New York, New York
    • Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Bldg. 35, Orangeburg, NY 10962.
    Search for more papers by this author
  • Hung-Teh Kao,

    1. Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York
    2. New York University Medical Center, New York, New York
    Search for more papers by this author
  • Barbara Porton

    1. Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York
    2. New York University Medical Center, New York, New York
    Search for more papers by this author

  • Please cite this article as follows: Chao HM, Kao H-T, Porton B. 2007. BDNF Val66Met Variant and Age of Onset in Schizophrenia. Am J Med Genet Part B 147B:505–506.

Abstract

Brain-derived neurotrophic factor (BDNF) has been advanced as a candidate gene for schizophrenia by virtue of its effects on neurotransmitter systems that are dysregulated in psychiatric disorder and its involvement in the response to antipsychotic drugs. The extensively examined BDNF gene Val66Met (or rs6265) variant has been associated with schizophrenia, and studies have linked this polymorphism to brain morphology, cognitive function, and psychiatric symptoms in schizophrenia. Moreover the BDNF Val66Met variant has been reported to be associated with age of onset in schizophrenia. Genotyping of African-American subjects with schizophrenia for five BDNF coding region single nucleotide polymorphisms revealed variance only at the Val66Met allele. The results of statistical analyses indicate a relationship between the BDNF Val66Met genotype and the ages of first psychiatric hospitalization and first schizophrenia symptoms. © 2007 Wiley-Liss, Inc.

Ancillary